Clay Siegall is a co-founder of the Seattle Genetics, which he co-founded in 1998. He has risen ranks to being the company’s President, Chief Executive Officer, and the Chairman of the Board of Directors. Siegall, a Ph.D. holder, is a scientist by profession and training with a specialization on several cancer therapies. His vast scientific knowledge in combination with a passion for assisting cancer patients prompted Siegall to build Seattle Genetics based on scientific innovation and drug development practices. Clay Siegall has offered guidance to the company up to its current leadership position and also in the development of antibody-drug conjugates. Seattle Genetics, under Siegall’s leadership, has also collaborated with Takeda Pharmaceutical, and together they have been able to make the ADC drugs available in more than sixty-five countries.
From an interview conducted by Ideasmench, the following is learned from Clay Siegall. The idea for Seattle Genetics came about with the aim of helping cancer patient after Clay watched his father have cancer, which later killed him. He has a goal of treating cancer patients all over the world and ensuring that they do better. As an entrepreneur, Clay says that people should associate with smart people with different skills so as to learn as much as they can. According to him, collaborating with other industries and leaders is a strategy that has helped the company grow to global heights.
Clay Siegall has worked for the Bristol-Myers Squibb Pharmaceuticals Research Institute for six years, the National Cancer Institute, and the National Institutes of Health. He has served as a Board of Director in different hospitals and institutions. Dr. Siegall has also received some awards for his contemporary work. He is an author by extension as he has fifteen patents and over seventy publications. Clay believes that with time, cancer drugs will be available to all cancer patients.